Cardiovascular Research Advance Access originally published online on January 24, 2009
Cardiovascular Research 2009 82(2):229-239; doi:10.1093/cvr/cvp001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protein kinase C in heart failure: a therapeutic target?
1 Department of Chemical and Systems Biology, Stanford University School of Medicine, CCSR, Rm 3145A, 269 Campus Drive, Stanford, CA 94305-5174, USA
2 School of Physical Education and Sport, University of São Paulo, SP 05508-900, Brazil
* Corresponding author. Tel: +1 650 725 7720; fax: +1 650 723 2253. E-mail address: mochly{at}stanford.edu
Heart failure (HF) afflicts about 5 million people and causes 300 000 deaths a year in the United States alone. An integral part of the pathogenesis of HF is cardiac remodelling, and the signalling events that regulate it are a subject of intense research. Cardiac remodelling is the sum of responses of the heart to causes of HF, such as ischaemia, myocardial infarction, volume and pressure overload, infection, inflammation, and mechanical injury. These responses, including cardiomyocyte hypertrophy, myocardial fibrosis, and inflammation, involve numerous cellular and structural changes and ultimately result in a progressive decline in cardiac performance. Pharmacological and genetic manipulation of cultured heart cells and animal models of HF and the analysis of cardiac samples from patients with HF are all used to identify the molecular and cellular mechanisms leading to the disease. Protein kinase C (PKC) isozymes, a family of serine–threonine protein kinase enzymes, were found to regulate a number of cardiac responses, including those associated with HF. In this review, we describe the PKC isozymes that play critical roles in specific aspects of cardiac remodelling and dysfunction in HF.
KEYWORDS Protein kinase C; Heart failure; Cardiac remodeling; Hypertrophy; Fibrosis and inflammation
Time for primary review: 21 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. S. Karliner and J. H. Brown Lipid signalling in cardiovascular pathophysiology Cardiovasc Res, May 1, 2009; 82(2): 171 - 174. [Full Text] [PDF] |
||||
